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Introduction
An early hope for monoclonal antibodies (mAbs) was that they 
would serve as tumor-specific magic bullets in two ways. As bul-
lets, they would move through the blood to reach and attack 
tumor targets. The exquisite specificity of a single antibody would 
provide the magic. Experience with tumors outside the brain has 
begun to justify this hope. Among the best-studied examples, 
the mAbs trastuzumab (Herceptin®), rituximab (Rituxan®) and 
bevacizumab (Avastin®), are now approved as part of the stan-
dard therapy for appropriate forms of breast cancer,1-4 B-cell lym-
phoma5,6 and colorectal cancer, respectively, as well as other types 
of cancer.7,8
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Monoclonal antibodies (mAbs) are used with increasing 
success against many tumors, but for brain tumors the blood-
brain barrier (BBB) is a special concern. The BBB prevents 
antibody entry to the normal brain; however, its role in brain 
tumor therapy is more complex. The BBB is closest to normal 
at micro-tumor sites; its properties and importance change 
as the tumor grows. In this review, evolving insight into the 
role of the BBB is balanced against other factors that affect 
efficacy or interpretation when mAbs are used against brain 
tumor targets. As specific examples, glioblastoma multiforme 
(GBM), primary central nervous system lymphoma (PCNSL) 
and blood-borne metastases from breast cancer are discussed 
in the context of treatment, respectively, with the mAbs 
bevacizumab, rituximab and trastuzumab, each of which 
is already widely used against tumors outside the brain.   
It is suggested that success against brain tumors will require 
getting past the BBB in two senses: physically, to better attack 
brain tumor targets, and conceptually, to give equal attention 
to problems that are shared with other tumor sites.
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Over time, we have become more sophisticated about both 
the bullet and its magic. For tumors outside the brain, long-term 
remissions can indeed be achieved, but not all eligible patients 
respond, responses may be short-lived and side effects can be lim-
iting.1-8 Many of the evolving insights and adaptations apply very 
generally to many different therapies or to tumors at many sites. 
Additional insights apply and new insights are still needed for 
tumor in the brain.
In applying mAb therapy to brain tumors, both expectations 
and interpretation are colored by awareness of the blood-brain 
barrier (BBB). A striking example is seen when tumors in the 
bodies of breast cancer patients respond to systemic mAb treat-
ment, but then metastases appear in the brain.9,10 The reason 
most often suggested for this phenomenon is that the BBB must 
be blocking access to the brain metastases, making the brain a 
sanctuary site; however, the full explanation must be more com-
plex. Accumulating experience suggests that systemic antibody 
can be beneficial for patients with brain metastases or with other 
targets in the brain. How can this be the case if access is blocked 
by the BBB? If access is not in fact limiting, how is late failure 
in the brain to be explained, especially when it occurs in parallel 
with tumor control at other sites?9-11
The questions above set the context for this review. To 
address them, brain tumors (the target), antibodies (the magic), 
how antibodies attack tumor (the bullet) and how they reach it   
(the barrier) are reviewed in turn. With this as background, prac-
tical experience with mAbs for brain tumor targets is re-visited 
(the findings) and ways to go forward are suggested (the future). 
As will be brought out, the special problems posed by the BBB 
are balanced by more general concerns. Indeed, one aspect of   
“getting past the BBB” will be to give greater attention to prob-
lems that are shared with other tumor sites.
The Target: Tumor in the Brain
Three tumor types. Three brain tumor types, each coupled to 
a mAb that has already been used extensively outside the brain, 
are discussed below (Table 1). Together, these antibody/target 154  mAbs  Volume 3 Issue 2
tumor, at any site, as well as practical difficulties in interpretation 
for targets in the brain.
Metastatic. Blood-borne metastases from other organs are 
many-fold more frequent than primary brain tumors; the most 
common sources are tumors of the lung and breast.9 For many 
tumors of origin, parenchymal metastases remain (at least ini-
tially) in the perivascular space (PVS);20 the infiltrative growth 
that is characteristic of glial brain tumors or PCNSL is not seen. 
Another difference from primary brain tumors is that, when 
patients appear to benefit from systemic mAb, the site of attack 
can be questioned; efficacy may reflect better control of systemic 
tumor, rather than of tumor in the brain itself. Interpretation of 
apparent benefit from systemic trastuzumab, used against human 
epidermal growth factor receptor 2 (Her2)-overexpressing meta-
static breast cancer, suggests this possibility.
Some common features. Need for new therapies. For each of 
the tumors described above, new therapies are needed. With cur-
rent therapy, the median survival after diagnosis of GBM is less 
than 15 months;12,13,15,21,22 survival can be similar or even shorter 
after diagnosis of brain metastases,23 or after relapse of PCNSL.19 
Micro-tumor targets. Microscopic tumor (or micro-tumor), 
tumor too small to be readily imaged by conventional methods, is 
an important component of many brain tumors, including those 
stressed here. For GBM or other glial brain tumors, infiltrative 
tumor is known to remain after a main tumor mass has been 
removed,12,15 PCNSL normally appears as a diffuse B-cell lym-
phoma17 and blood-borne tumor from other organs first enters 
the brain as micro-metastases.
For the many cases where it is known that micro-tumor is 
likely to be present somewhere in the brain, but not exactly 
where, localized therapies are not appropriate. This increases 
interest in agents such as mAbs that are less inherently toxic 
than the conventional therapies,24,25 and so safer for widespread 
delivery. For tumor outside the brain, a complementary attrac-
tion is that most therapies are thought most likely to succeed 
against micro-tumor, as opposed to larger masses.26 A confound-
ing factor in the brain is that the BBB is closest to normal, and 
therefore most effective at blocking antibody access, at micro-
tumor sites. A related problem is that, although the importance 
of brain micro-tumor is widely acknowledged, it is rarely targeted   
explicitly in pre-clinical work.27,28
The challenges of treating brain tumor targets are well illus-
trated by experience with the mAbs listed in Table 1. Before 
turning to the clinical findings, it is useful to briefly review prop-
erties of the mAbs themselves.
combinations illustrate different challenges to using mAbs and to 
interpreting their effects against targets in the brain.
Glioma. Among primary brain tumors (those that arise within 
the brain), the high grade glioma, glioblastoma multiforme 
(GBM), is the most common and aggressive type in adults.   
As such, GBM has been the focus of much work with mAbs, as 
well as other new therapies.12-15
GBM has a complex growth pattern (Fig. 1). There is typi-
cally a tumor mass (or more than one) that is easily detected with 
conventional imaging. The tumor mass does not have a sharp 
border. Instead, individual tumor cells infiltrate the brain paren-
chyma and may be widely disseminated at the time of diagnosis. 
The tumor mass and the infiltrative component present differ-
ent challenges to mAb therapy.12,15 Experience with bevacizumab 
draws attention to the many possible effects of a single antibody, 
especially when coupled to heterogeneity within the tumor itself.
Lymphoma. The second tumor emphasized, primary central 
nervous system lymphoma (PCNSL), is also considered “pri-
mary” because it is normally confined to the central nervous sys-
tem (CNS); the actual origin is not known.16-18 PCNSL occurs 
in two very different contexts: in patients with AIDS or other 
forms of immunosuppression and also in immunocompetent 
patients.17-19 Although there are important differences between 
PCNSL in these different contexts, one common feature is that, 
like other lymphoid cells, normal or neoplastic, PCNSL can infil-
trate the brain parenchyma.16-19 A second common feature is that 
PCNSL is most often derived from B cells.17-19
Rituximab, first used against B-cell lymphomas outside the 
brain, is now being used in related contexts in the CNS. Its use 
brings out aspects of antibody specificity that are relevant for any 
Table 1. Tumor/antibody combinations emphasized in the text
Brain tumors discussed Antibodies discussed Target antigens
General type Specific example Name How modified Name Unique to tumor?
glioma GBMa bevacizumab (Avastin) humanized VEGFc No
lymphoma PCNSLb rituximab (Rituxan) chimeric CD20d No
metastatic breast cancer trastuzumab (Herceptin) humanized Her2e No
aGBM, glioblastoma multiforme; bPCNSL, primary central nervous system lymphoma; cVEGF, vascular endothelial growth factor; dCD20, common B-cell 
antigen;eHer2, human epidermal growth factor receptor 2
Figure 1. Two patterns of tumor growth in the brain. Tumor often 
grows around blood vessels (left), but some tumors can also infiltrate 
the brain parenchyma (right).www.landesbioscience.com mAbs  155
the brain. Complexes between an antibody and its target anti-
gen can stimulate the patient’s own immune response or mAbs 
can modulate an ongoing response.30,38,42 Complementing these 
spontaneous activities, additional effector mechanisms come into 
play when mAbs are coupled to agents, such as radionuclides or 
toxins,24,40 or larger molecules or particles (liposomes, nanopar-
ticles),24,43-45 so that the mAb serves a targeting function and the 
other component provides (or adds to) the attack mechanism. 
The sequence of the antibody protein itself may be modified 
to alter target binding or constant region functions,42 or avoid   
having the antibody recognized as a foreign protein by the 
patient’s immune system. All three antibodies discussed here 
were modified to reduce such recognition (Table 1).40 The vari-
ety of possible effector mechanisms is multiplied as antibodies are 
used in combination with other agents or modalities.37 Of par-
ticular relevance for brain tumor, radiotherapy is thought to alter 
the BBB in ways that increase antibody access to tumor sites.23,44
Even where antibody-mediated therapy has been most success-
ful, the key effector mechanisms are not yet known.2,6,32,35,36,38,40 
Not only is there a wealth of possibilities, but the balance of 
effector functions may differ at different tumor sites.12 The 
frequent use of combination therapies and the potential long-
term effects of previous treatments further increase the dif-
ficulty of defining the effect of a given antibody. There may 
also be uncertainty as to where an antibody exerts its effects, 
for example, whether metastatic tumor is attacked at its source,   
en route or at its final site. In the brain, interpretation is further 
impeded by the difficulty of directly analyzing the tumor site. 
These uncertainties, in turn, complicate interpretation of the 
role of the BBB.
The Magic: What Tumor-Specific Can Mean
Although antibody specificity is indeed exquisite,29 few determi-
nants are limited to tumor cells (Fig. 2).24,30 Fortunately, shared 
molecules can serve as practical tumor targets and this is true for 
each molecule targeted by the mAbs in Table 1.
Each B-cell lymphoma expresses a unique idiotype, and this 
may well be the target of choice in the long term.31 Rituximab, 
in contrast, recognizes a common B-cell antigen, CD20, that is 
expressed by both normal and neoplastic B cells. At present, the 
advantage of rituximab is that it can be used for many different 
patients, coupled to the fact that the depletion of normal B cells 
can be tolerated because existing antibody and antibody-forming 
plasma cells are spared, other protective mechanisms remain 
active and B cells are eventually replaced.32,33
Although more restricted antigens are known for GBM,34 
there has been enormous interest in using bevacizumab to tar-
get vascular endothelial growth factor (VEGF), which promotes 
angiogenesis for tumors, but also in normal wound healing.35 
Trastuzumab targets Her2, which is overexpressed in many 
breast cancers, but also expressed by normal cells.1,24,36 In prac-
tice, each of these three mAbs has been used successfully against 
tumor outside the brain1-8 and, increasingly, is being used against 
brain tumor targets.
Although targets need not be limited to strict tumor-specific 
antigens, cross-reactions may cause problems for individual 
patients. More generally, the problem of resistance is increas-
ingly acknowledged.2,4,12,37,38 For any given mAb, a tumor cell 
can escape attack at many levels, from its expression of the tar-
get determinant, to its susceptibility to the final effector mecha-
nism.12,31,37-39 Probing the basis of resistance is complicated by 
uncertainty as to which, among many possibilities, are the most 
important effector mechanisms for a given mAb, tumor and 
site.
The Bullet: What Antibodies Can Do
Antibodies can lead to death or arrest of a tumor target in a great 
and growing variety of ways, with new antibody-mediated func-
tions still being identified. Antibodies can directly block activity 
of a target molecule simply by binding to it, through the anti-
body variable region,36,40 while additional functions are brought 
to bear if the constant (Fc) region is engaged. The benefits of Fc 
binding to elements of the complement cascade or cell-bound Fc 
receptors are well known.36,40 More recently appreciated is that 
another kind of Fc receptor, FcRn, binds to an antibody in a 
way that protects it from degradation. This contributes to the 
prolonged serum half-life of an antibody, as compared to that of 
most other proteins.26,41
An antibody need not attack tumor cells themselves. 
Bevacizumab, which is intended to block development of a 
tumor’s blood supply, is an example.35 Also, the antibody does 
not necessarily need to attack its target in the brain. Blood-
borne tumor or other targets may be attacked before they reach 
Figure 2. Distribution of tumor antigens. A tumor cell displays a 
characteristic combination of components, many of which are also 
expressed by normal cells. Even though they may not be unique to the 
tumor, shared antigens can serve as practical tumor targets.156  mAbs  Volume 3 Issue 2
proteins.50 An important consequence is that the distribution of 
a contrast-enhancing agent does not necessarily reflect the distri-
bution of therapeutic agents.
Tumor-associated vessels may be leaky, but are also tortu-
ous and chaotic, so that, even if blood-borne molecules do leave 
the vessel, they may not be evenly distributed within the tumor. 
Factors such as an unfavorable pressure gradient and the nature 
of the extracellular matrix can impede the ability of therapeutics, 
including antibodies, to become well-distributed within a tumor 
mass, while the center of a large tumor can act as a sink.26,44,50,51 
In GBM in particular, blood-borne agents will accumulate in the 
necrotic center, with its disrupted BBB, rather than at the infil-
trative edge, where the BBB is more like that of normal brain.50 
Properties of the tumor cell itself can further impede antibody 
binding or efficacy. Most of these factors are not unique to brain 
tumors; rather, they can impede the distribution or activity of 
antibody or other therapy against solid tumor at any site.26,40
In the brain, interpretation of antibody levels is hampered by 
the difficulty of taking local measurements. Instead, the con-
centration of therapeutic agents is often followed by measuring 
levels in cerebrospinal fluid (CSF). This approach does not take 
into account anatomic and metabolic heterogeneity even within 
the normal brain, and potential inaccuracy is additionally com-
pounded by heterogeneity among tumor sites.44,46,49,52 Even at 
a single site, antibody access can change with time. As tumor 
either responds to therapy or continues to grow, the BBB itself, 
as well as the other impediments to antibody access, will change 
accordingly.17,18,53
The Findings:  
Experience with Three Brain Tumor/Antibody Pairs
The topics discussed so far provide a context for reviewing clini-
cal experience with mAbs in brain tumor therapy. Three of the 
best-studied antibody/target combinations (Table 1) illustrate 
specific details.
Bevacizumab and GBM. The original intention was that 
bevacizumab would bind VEGF and so attack the highly vas-
cular main tumor mass indirectly, by depriving it of its blood 
supply.15,35,54 In practice, the antibody does affect tumor blood 
vessels, reducing their leakiness and other abnormal properties. 
Benefits of this vessel normalization include reduced edema and 
intracranial pressure, which permits reduced steroid use,15,54 and 
perhaps also protection against radiation necrosis.55,56
The effect on tumor growth per se has been hard to inter-
pret. Because it affects blood vessels, bevacizumab also affects 
extravasation of the contrast agents used to image a tumor mass. 
In this situation, improvement in the radiographic image can be 
misleading: It may simply reflect reduced extravasation of the 
contrast agent rather than tumor control.15
The disseminated components of GBM present complemen-
tary challenges. Individual infiltrative cells do not depend on 
angiogenesis.15 On the contrary, it has been suggested that, in 
response to bevacizumab, infiltrative growth, as well as other 
forms of parenchymal invasion, may even be increased.15,22,54,57 
The effect of bevacizumab on drug delivery is also complex. 
The Barrier: How Entry to the Brain is Controlled
The ability of the BBB to block passive entry of therapeutics 
into the normal brain is well known; however, understanding of 
the BBB, even in the normal brain, is still evolving. The BBB is 
dynamic and can be manipulated; unfortunately, it is not the 
only impediment.
Entry to normal brain.  What impedes entry. In the brain 
parenchyma, the anatomical BBB is formed by specialized tight 
junctions between the endothelial cells of cerebral micro-vessels, 
together with astrocyte endfeet that abut the endothelium, adja-
cent pericytes and a characteristic composition of the extracel-
lular matrix (ECM). This anatomical barrier is complemented 
by a physiological barrier that includes reduced pinocytosis by 
the endothelial cells (as compared to other tissues), degradative 
enzymes and transporters that act as efflux pumps to actively 
return many kinds of molecules, including many drugs, to the 
blood. Other CNS compartments have variations of these prop-
erties, so that the brain environment remains controlled.45-47
What allows entry. As effective as the BBB is in preventing 
unregulated entry of substances from the blood, it is equally 
effective at selectively permitting entry of necessary compo-
nents. Active transporters import nutrients and regulatory mol-
ecules.44-47 One approach to delivering agents to the brain is to 
exploit these transporters.44,45
Of special relevance for antibody therapeutics, FcRn, the Fc 
receptor that protects antibodies from degradation in serum, is 
highly expressed on brain vessels.41 In other organs, another func-
tion of FcRn is to transport antibody across tissue barriers. For the 
brain, a role in removal of harmful antibody from the brain has 
been suggested,41,42 but the actual roles are not yet known. In other 
tissues, FcRn-mediated transport is bi-directional, and the pre-
dominant direction can be modified experimentally.48 It is intrigu-
ing to consider whether FcRn might also act to bring antibody into 
brain tumor sites—or might be exploited for that purpose.
Entry to tumor sites. Not static. The BBB is dynamic, its 
properties specified and maintained by reciprocal interactions 
with adjacent cells. BBB properties change during development 
and other normal processes, as well as in the context of inflam-
mation or other pathology,45-47,49 including tumor growth.44,50 
The BBB may be essentially normal at micro-tumor sites; as the 
tumor grows, the BBB is progressively disrupted. Ultimately, 
new vessels may be formed and the tumor itself modulates their 
properties.50 Indeed, for brain metastases, tumor-adjacent vessels 
may resemble abnormal versions of vessels in the tissue of origin, 
rather than brain barrier vessels.44,50
Not the only impediment. When primary or metastatic brain 
tumor can be imaged by a contrasting-enhancing agent, typi-
cally gadolinium, the vessels must be at least leaky enough to 
permit the agent’s extravasation. Unfortunately, this does not 
necessarily imply effective delivery of mAbs. Even in the normal 
brain, the distribution of a given molecule will vary with its size, 
shape, charge, composition (such as lipophilicity) and the extent 
to which it binds to blood components or tissue.26,45,46 As two 
examples of the relevance of these factors, antibodies are much 
larger than gadolinium23 and many drugs bind tightly to serum www.landesbioscience.com mAbs  157
are thought to contribute to pathology.32,59 In this case, interpre-
tation is aided by simpler treatments and well-controlled studies. 
Although rituximab shows efficacy in MS, the mechanism and 
sites of action are not known. In particular, because autoimmune 
B cells must enter the brain from the blood, efficacy does not 
necessarily reflect attack of targets in the brain.59
Trastuzumab and metastastic breast cancer.  The chal-
lenge of late brain metastases. As use of trastuzumab for Her2-
overexpressing breast cancer became widespread, a troubling 
finding was an apparent increase in brain metastases.3,10,23,60 
The reasons are not known. Brain metastases are typically a late 
occurrence in breast cancer,10,23,60,61 and so longer survival itself is 
relevant.3,23,60 The BBB is often assumed to be important;10,23,60,61 
however, its role depends upon a point that is often not explicitly 
discussed: Brain metastases often occur in parallel with tumor 
control at other sites.9,10 If the patient has responded to antibody 
therapy in the periphery, what can be the source of the newly-
detected brain metastases? Two possibilities imply different roles 
for the BBB (Fig. 3).
Model 1. New blood-borne tumor. Late brain metastases may 
represent new blood-borne tumor from outside the brain, perhaps 
from known sites of apparently stable disease or from undetected, 
dormant tumor elsewhere. Eventually, this tumor begins to grow 
and provides a source of new blood-borne metastases.62 In this 
case, if systemic mAb therapy is continued even after tumor is no 
longer detected in the periphery, it may attack the potential brain 
metastases at their original site or in the blood (Fig. 3A), before 
the tumor even enters the brain; the BBB need not be involved. 
Since this tumor has escaped that particular mAb in the periph-
ery, switching to a different therapeutic agent may be preferable. 
Of course, once the tumor enters the brain, the role of the BBB 
would change as the tumor grows, just as in Model 2.
Model 2. Dormant tumor in the brain. As an alternative   
scenario, tumor may have entered the brain long before it is 
detected and remained, undetected, as micro-metastases3 in 
a dormant state. As long as the BBB is close to normal, then 
Normalizing the vessels may improve distribution of blood-borne 
agents within a tumor mass,50 but may also impede their extrava-
sation, by restoring the BBB.15
More general factors, not limited to brain tumors, also impede 
interpretation of an antibody’s effects. Many reports of brain 
tumor findings concern small studies and many depend on his-
torical controls.15,21,22 Moreover, the antibody is normally part 
of a complex regimen, including surgery, radiation and chemo-
therapy, and is often given in combination with (further) chemo-
therapy.15,21,22 All these factors make it hard to define the effect 
of the antibody itself on tumor growth. Other questions concern 
response criteria. How to weigh overall survival as opposed to 
progression-free survival; the possibility that high statistical sig-
nificance may reflect relatively small quantitative differences in 
the response and the possibility that a responsive subgroup may 
go undetected are concerns that apply to all tumors. When there 
is apparent benefit, the same limitations seen in other contexts 
apply: as with other tumors, benefits of bevacizumab for GBM 
patients are transient.22,54 As happens after treatment with other 
new therapies, GBM normally recurs.22
Rituximab and PCNSL. Rituximab targets the common 
B-cell marker CD20. Outside the brain, it shows efficacy in 
patients with different kinds of B-cell lymphoma.5,6 In the brain, 
its specificity is appropriate for PCNSL, which is typically a B-cell 
lymphoma. On the other hand, the BBB is likely to block anti-
body access to sites of infiltrative tumor, and this is also typical 
of PCNSL. This suggests that full efficacy may require actively 
delivering antibody across the BBB.44,51,52
In practice, the potential efficacy of rituximab against 
PCNSL, with or without BBB opening, is not yet known. 
Although increasing, PCNSL is still rare;18 most reports of ritux-
imab use describe small studies and the antibody is often given 
as part of a complex therapy, without internal controls.53,58 Given 
these limitations, work in a related context is relevant.
Systemic rituximab has shown efficacy for patients with auto-
immune diseases, especially multiple sclerosis (MS), where B cells 
Figure 3. A varied role for the BBB. Possible relationships among tumor (black circles), gadolinium (Gd, black dots), antibody (AB, Y shapes), blood 
vessels (grey) and the blood-brain barrier (BBB), under different conditions of tumor growth are depicted.158  mAbs  Volume 3 Issue 2
meningeal tumor, where other delivery routes are of special inter-
est.68,69 The points raised should help to interpret findings for a 
variety of delivery strategies and tumor sites.
The Future
The natural evolution of mAb therapy for any tumor at any site 
is towards redundancy and refinement. Redundancy, in the sense 
that alternative targets are identified and alternative antibodies 
are prepared against promising targets, old or new. Refinement, 
in the sense that the new antibodies can be designed to solve 
specific problems: to avoid known cross-reactions or to work by 
means of alternative effector mechanisms. Refinement of another 
kind will come from combining therapies in more directed ways, 
in parallel with growing understanding of the underlying mecha-
nisms of tumor growth, susceptibility and resistance. Combined 
targeting of a GBM tumor mass plus infiltrative tumor or exist-
ing brain metastases plus tumor that has not yet reached the 
brain are obvious examples. Improved clinical trial design will 
be important for all tumors,70 as will more predictive pre-clinical 
models.27,28
As for mAbs themselves, two parallel approaches are each 
likely to be fruitful. One is to continue to refine the specificity 
and modifications of the antibody molecule itself. The other is 
to synthesize novel agents, using knowledge of antibody struc-
ture and function as a guide.71 Even as novel agents evolve, the 
whole antibody molecule still has great value. It has a long half-
life and can mediate multiple functions, with new functions and 
uses still being identified. Indeed, the key mechanisms used by 
even the most successful antibodies in human patients are not yet 
established.
For all solid tumors, a complementary evolution of both 
understanding and technology is needed to improve delivery of 
therapeutics to larger tumor masses. For the brain, where deliv-
ery to micro-tumor is an equal challenge, clearer understanding 
of the nature and role of the BBB, complemented by improved 
methods for opening or bypassing it when necessary, have been 
long-standing goals.44,51 A third approach has received less atten-
tion: In other clinical contexts, sustained antibody synthesis 
occurs within the CNS.32,59 This too should be exploitable for 
brain tumor patients.72
In the long run, how will mAb therapeutics benefit brain 
tumor patients? We may depend on antibody itself, a fragment 
or a synthetic alternative; the agent may be delivered passively 
or actively made within the brain; it may attack brain tumor 
directly or “only” targets outside the brain (such as blood-borne 
metastases or tumor vasculature); or even less directly, it may 
act to simulate or modify an endogenous response. Most likely, 
each variation will have its role. In planning and interpreting 
antibody therapy, the BBB has rightly commanded attention, yet 
its importance is balanced by that of more general problems of 
access and resistance. Going forward, a matching focus on chal-
lenges that are common to other agents, other tumors and other 
sites will be a complementary way of getting past the BBB.
contrast-enhancing agents, such as gadolinium, would not reveal 
this tumor and antibody therapeutics would not reach it (Fig. 3B). 
Once the tumor begins to grow, the BBB might initially be compro-
mised enough for gadolinium, but not antibodies, to extravasate   
(Fig. 3C). The tumor could thus be detected radiographically, 
but not treated.
As the tumor continues to grow, the barrier will break down 
further and antibody may then extravasate (Fig. 3D). Therefore, 
if the same mAb treatment is continued, it may show efficacy 
eventually. Actively delivering the antibody across the BBB 
should allow for an earlier response. If the tumor grows too 
large before antibody is given, impediments besides the BBB will 
become increasingly important in blocking distribution of the 
antibody, even if it does leave the vessel (Fig. 3E).
The ability of systemic antibody to help control brain metas-
tases would thus vary with the tumor’s current site (that is, 
whether or not is was already in the brain) and size, as depicted in   
Figure 3 as idealized examples. Brain metastases are heteroge-
neous, even within an individual,20 and may differ in the time of 
entry to the brain, susceptibility to the antibody in question and 
BBB status; moreover, each of these factors can change with time. 
Even with these caveats, the models compared above can help 
to interpret clinical findings, especially partial or disappointing 
responses.
In practice. Several authors have suggested that systemic anti-
body should be continued after brain metastases are detected 
in breast cancer patients and evidence of benefit has been 
reported.63-67 Interpretation is complicated by the same factors 
discussed above: Many studies are small or anecdotal and mul-
tiple modalities or agents may be involved. When there is appar-
ent benefit, the key sites are not known. As many authors discuss, 
benefit from systemic antibody may simply reflect better control 
of systemic disease; it does not necessarily reflect direct attack 
of tumor in the brain.63-65,67 In practice, the potential for direct 
attack is likely to vary among different metastases and to change 
with time (Fig. 3).
Summary of clinical experience. There is evidence that sys-
temic mAb treatment can benefit patients with brain tumors or 
other CNS pathology. The nature and site of antibody activity 
are less clear. The extent to which antibody enters—and acts 
at—tumor sites within the brain itself is not known. A conserva-
tive interpretation is that bevacizumab primarily reduces edema, 
and rituximab and trastuzumab act primarily on systemic tar-
gets. The complexity of tumor therapy, difficulty of direct local 
measurements, limitations of clinical trials and drawbacks of pre-
clinical models all complicate interpretation of clinical results. 
Regardless of whether the antibody acted in the brain or else-
where, an increase in overall or progression-free survival, or sim-
ply an improved quality of life, are certainly of benefit to brain 
tumor patients. The goals for the future are, as for all tumors, to 
increase the benefit and reduce the cost of the therapeutics.
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